GPT and anemia: The most common TEAEs in gilteritinib-treated patients were febrile neutropenia (55%), increased AST (52%), increased ALT (46%), anemia (39%), constipation (39%), increased blood creatinine phosphokinase (39%), decreased platelet count (39%), and nausea (36%) (Table 5).